Company Overview
American HealthCare Capital is pleased to exclusively introduce a premier research institution specializing in Biomedical Research that provides global genomic profiling and molecular diagnostics services to academic centers, the pharmaceutical and biotech industries, oncologists, and pathologists with innovative diagnostic, prognostic, predictive, and personalized testing. They do this in three component stages of clinical research: Problem Definition, Project Design, and Data Discovery.
This business has a combination of unparalleled quality diagnostics, industry leading innovations, and exceptional services, enabling them to help a range of clients develop and implement a specialized approach to healthcare and ultimately eradicate the most malicious disease state
Financial Overview
The business is CAP accredited and is a CLIA licensed and certified lab with over 850 clients. The payor breakdown is as follows: 55% from Academic Research institutes, 40% from Biotech The majority of their referrals come from existing clients and research publications.
Over the past 25 years, the company has averaged over $5 million per year with a net profit margin of 75%. Ownership is working on growing the volume of business and keeping the high profitability and margins in place.
Exit Plan
The current owner is pursuing the sale to concentrate on other businesses ventures. To facilitate a successful and orderly transition, the owner is willing to remain with the Company during a transitional period to ensure that the new buyers have met all key clients and understand the operations. The owner is also open to staying on as a consultant or part-time employee if needed after the transition.
Asking Price
The asking price for this opportunity is To Be Determined (TBD).